No matches

196 search results for: burden of disease

Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
Dermatology
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.

View more
EADV 2025
On Demand
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

View more
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Pulmonology
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Infographic

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

View more
Beyond Age: Unraveling the Mortality Risk in Bullous Pemphigoid
Dermatology
Beyond Age: Unraveling the Mortality Risk in Bullous Pemphigoid
expert video

Dr. Donna Culton discusses the elevated mortality risk in patients with bullous pemphigoid at EADV 2025

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region